The value of independence and transparency

OMeGA serves all residency and fellowship programs in the Americas regardless of size, location, or scope.  Grants are available in all nine fellowship sub-specialties.

Independent of personalities or affiliation
OMeGA was founded by the American Orthopaedic Association (AOA) (www.aoassn.org) as an independent legal entity that is not controlled by the AOA. OMeGA’s affiliation with AOA or any other professional organization or commercial interest has absolutely no bearing on the evaluation of proposals or the awarding of grants.

An independent board
OMeGA board members may not have any current ties to industry nor have received any remuneration from industry sources for at least two years prior to serving.  Ownership of less than 5% in publicly traded securities and mutual funds in any orthopaedic medical device, pharmaceutical and biotechnology companies will not be considered a Financial Interest.  Individuals have no leadership roles in orthopaedic fellowship or residency programs and educational institutions that may apply for a grant.  “Leadership Role” is defined to include a department chair or other position that involves financial decision making within the orthopaedic department of an institution in the previous two (2) years.  Individuals will recuse him/herself from consideration of grant applications made by institutions with which he/she has been associated in the last two (2) years.
 

Established, objective criteria
OMeGA awards grants based on established objective criteria and not on the use, order, or purchase of (or the recommendation to use, order or purchase) any products or services of any specific medical device, pharmaceutical and biotechnology companies. Grant recipients must provide absolute assurance that the funds they receive will not affect professional judgment or patient care decisions.

OMeGA actively solicits and appreciates funding from industry, professional, and individual donors who wish to support the advancement of orthopaedic medicine and education. While donors may direct their contributions to specific subspecialty areas, they have no role in directing funds to specific programs or candidates.  The OMeGA grant approval process is in full accordance with the recommendations and the guidance of the Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), and the Advanced Medical Technology Association (AdvaMed).  In addition, OMeGA does not request the name of the fellow who will benefit from funding in the application process as recommended by the American Association of Medical Colleges (AAMC) Task Force on Industry Funding of Medical Education. 

An independent review committee
OMeGA review committee members may not have any current ties to industry nor have received any remuneration from industry sources for at least two years prior to serving.  Ownership of less than 5% in publicly traded securities and mutual funds in an orthopaedic medical device, pharmaceutical and biotechnology companies will not be considered a Financial Interest.  Individuals will disclose all leadership roles in orthopaedic fellowship or residency programs and educational institutions that may apply for a grant, recusing him/herself from consideration of grant applications made by institutions with which he/she has been associated in the last two (2) years.  “Leadership Role” is defined to include a department chair or other position that involves financial decision making within the orthopaedic department of an institution in the previous two (2) years.


2017 Review Committee

Ngozi M. Akabudike, MD
University of Maryland

Hisham M. Awan, MD
The Ohio State University
John A. Bergfeld, MD
Cleveland Clinic

Gregory K. Berry, MD
Montreal General Hospital
Jesse E. Bible, MD
Penn State Hershey

Walton W. Curl, MD
Wake Forest
Alexander J. Ghanayem, MD
Loyola University

Syed Ashfaq Hasan, MD
University of Maryland
David H. Kim, MD
Colorado Permanente Medical Group
Bassam A. Masri, MD
University of British Columbia

Elizabeth M. Nolan, MD
University of Oklahoma

William T. Obremskey, MD
Vanderbilt University
Michael A. Simon, MD
University of Chicago

William W. Tomford, MD
Massachusetts General Hospital

Brian C. Toolan, MD
University of Chicago




Committed to transparency

OMeGA will report annually on funded programs including feedback on the use of funds, resulting research, additional funding received, and other details of program operation. This not only ensures appropriate use of funds and absence of conflicts of interest, it can also contribute to continuous improvement of orthopaedic graduate medical education and training.

For current information attained from industry and the Center for Medicare and Medicaid Services (CMS) website regarding OMeGA Board and Review Committee members, view the 2016 OMeGA Transparency Report.